Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/materialsB

1	Controlling Whole Blood Activation and Resultant Clot Properties by Carboxyl and Alkyl
2	Functional Groups on Material Surfaces: A Possible Therapeutic Approach for Enhancing Bone
3	Healing
4	
5	
6	Hoi Ting Shiu, Ben Goss*, Cameron Lutton, Ross Crawford, Yin Xiao*
7	
8	
9	Running title: Blood clot and bone regeneration
10	
11	
12	Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane,
13	Queensland, QLD 4059, Australia
14	
15	
16	Keywords: biomaterials, coagulation, bone, growth factor, surface chemistry.
17	
18	*Corresponding author
19	Prof. Yin Xiao and Dr Ben Goss
20	Bone and Tissue Engineering, Institute of Health and Biomedical Innovation, Queensland
21	University of Technology, Kelvin Grove Campus, Brisbane, Qld 4059 Australia
22	Tel: +61 7 3138 6240
23	Fax: +61 7 3138 6030
24	
25	E-mail: <u>yin.xiao@qut.edu.au</u> , <u>bgoss@nuvasive.com</u>
26	

27

28 Abstract

29 Most research virtually ignores the important role of a blood clot in supporting bone healing. In this 30 study, we investigated the effects of surface functional groups carboxyl and alkyl on whole blood 31 coagulation, complement activation and blood clot formation. We synthesised and tested a series of 32 materials with different ratios of carboxyl (-COOH) and alkyl (-CH₃, -CH₂CH₃ and -(CH₂)₃CH₃) 33 groups. We found that surfaces with $-COOH/-(CH_2)_3CH_3$ induced a faster coagulation activation 34 than those with -COOH/-CH₃ and -CH₂CH₃, regardless of the -COOH ratios. An increase in -35 COOH ratios on -COOH/-CH₃ and -CH₂CH₃ surfaces decreased the rate of coagulation activation. 36 The pattern of complement activation was entirely similar to that of surface-induced coagulation. 37 All material coated surfaces resulted in clots with thicker fibrin at denser network at the 38 clot/material interface and a significantly slower initial fibrinolysis when compared to uncoated 39 glass surfaces. The amounts of platelet-derived growth factor-AB (PDGF-AB) and transforming 40 growth factor- β (TGF- β 1) released from an intact clot were higher than a lysed clot. The release of 41 PDGF-AB was found to be correlated with the fibrin density. This study demonstrated that surface 42 chemistry can significantly influence the activation of blood coagulation and complement system, 43 resultant clot structure, susceptibility to fibrinolysis as well as release of growth factors, which are 44 important factors determining bone healing process.

45

46

47

- 48
- 49

50 1. Introduction

51 Severe bone damage requires bone tissue engineering, which aims to provide three key elements for 52 bone repair: the scaffolding for osteoconduction, growth factors for osteoinduction, and progenitor cells 53 for osteogenesis^{1, 2}. To date, no engineered material outperforms autograft in bone-forming ability³. 54 Therefore, further understanding of how biomaterials used for scaffolds interact with host tissue and 55 affect bone formation will be helpful for the improvement of tissue engineering⁴.

56 Platelet-rich plasma (PRP) which has been applied in clinical dentistry for over a decade provides an 57 insight into the microenvironment required. PRP is a fraction of plasma with a high concentration of platelets and serves as an autologous source of growth factors⁵. Studies have shown that formation of 58 PRP gels to bone grafts or biomaterials increases the rate of bone formation and bone density⁶, possibly 59 due to increased concentrations of growth factors derived from platelets, and adhesive binding of graft 60 particles by the fibrin network⁷. However, other groups have shown conflicting results when PRP clots 61 62 were prepared with different platelet numbers and thrombin concentration⁸. Thus, these findings imply 63 that the effect of clots on bone healing depends on how the clots are formed.

During clot formation, thrombin concentration is known to affect fibrin thickness and density^{9, 10}. Whilst 64 abnormal changes in clot structure have been shown to influence the viscoelastic properties ^{11, 12} and 65 lysis rate of clots¹³, leading to pathological conditions such as cardiovascular thrombosis and bleeding 66 disorders^{14, 15}. Indeed, dental implant has long demonstrated that a peri-implant clot plays an important 67 role in endosseous healing¹⁶. Chemokines released from entrapped blood cells and fibrin network of the 68 69 peri-implant have been shown to support continuous recruitment and migration of osteogenic cells, resulting in a direct bone formation on the implant surfaces¹⁷. Thus the ability to control the properties 70 71 of a blood clot formed on the implant appears as a critical design parameter which would influence 72 cellular response and tissue ingrowth in bone healing.

Upon implantation, activation of blood coagulation occurs rapidly when whole blood makes contact
with the surface of a synthetic implant. The adsorption of plasma proteins is believed to initiate platelet

75 reactions and coagulation activation, leading to the generation of thrombin and fibrin, and ultimately formation of a blood clot on the implant surface¹⁸. Despite this phenomenon is generally being aware of, 76 77 few studies have explored early blood-endosseous implant interactions and resulting blood clot 78 formation, even if these events occur prior to bone regeneration. A peri-implant clot may be beneficial 79 for bone repair when the clot has biological and structural properties similar to those of the haematoma 80 formed on injured bone during native healing. On the other hand, an important concern of the blood-81 biomaterial interactions is the activation of the complement pathway and its potential to initiate chronic 82 inflammation or foreign body reaction (FBR). These adverse reactions may cause the deterioration of 83 the implanted biomaterial and secondary injury to surrounding tissue.

84 To minimise immunogenic and improve anti-thromboticity of blood contacting devices, many research 85 has been focused on modifying surface chemistry of biomaterials, particularly the species and density of 86 surface chemical functionalities. Alkythiols or alkysilanes self-assembled monolayers (SAMs) are often 87 used as a flat surface model. SAMs presenting 47% –COOH/53%–CH₃ chemical functionalities have 88 been shown to increase coagulation activation resulting in a strong fibrin fibre deposition, whereas 89 decrease leukocyte accumulation and complement initiation when compared with pure -COOH and -CH₃ SAMs ¹⁹. In addition, it has been found that poly (alkyl methacrylates) with different chain length 90 of alkyl groups provide further level to regulate these blood-biomaterial interactions 20 . Coincidently, 91 92 poly (methyl methacrylate) (PMMA) is widely used as a bone cement, dental fillings and intraocular lenses ²¹. Polymers containing ethyl methacrylate (EMA) or butyl methacrylate (BMA) have also been 93 shown to modulate chondrocyte and osteoblast attachment, and induce angiogenesis, respectively ^{22, 23}. 94 95 Specifically, copolymers composed of methyl methacrylate (MMA) and acrylic acid (AA), which 96 presents -COOH groups, has been confirmed to be non-toxic both in vitro and in vivo and served as a drug delivery system²⁴. Unlike SAMs on gold substrates which is not clinically feasible, such 97 98 copolymers of alkly methacrylate and acrylic acid may provide a coating to form the basis of three-99 dimensional material surfaces in developing a prothrombogenic and immunocompatible coating for 100 synthetic bone implants.

101 Given that most current approaches in bone tissue engineering focus solely on the replacement of viable 102 cells, growth factors, and functional structure using engineered scaffolds, it often overlooks the 103 importance of blood clot formation around scaffolds in controlling bone healing. In this study, we 104 hypothesised that the bone-inducing ability of a biomaterial may be improved by controlling the blood-105 biomaterial interactions and forming a desirable peri-implant blood clot with appropriate properties. We 106 developed an *in vitro* incubation vial where the inner surface was coated with materials of acrylic acid 107 (AA) and methyl (MMA), ethyl (EMA), or butyl methacrylates (BMA) at varied ratios. The effect of 108 surface functional groups and their relative ratios on coagulation and complement activation as well as 109 alterations in resultant clot structure, susceptibility to fibrinolysis and the release of platelet-derived 110 growth factor (PDGF-AB) and transforming growth factor-B1 (TGF-B1) were investigated.

- 111
- 112 **2.** Materials and Methods

113 2.1. Synthesis of materials: Acrylic acid and alkyl methacrylate were reacted via free-radical 114 polymerisation using benzoyl peroxide (BPO) as an initiator. Three types of alkyl methacrylates 115 were employed: methyl methacrylates (MMA), ethyl methacrylates (EMA) and butyl methacrylates 116 (BMA). The monomer solutions were added at molar ratios (AA: alkyl methacrylate; 45, 55 or 117 65 %) in a glass vial containing 0.5% of BPO. The solutions were deoxygenated by bubbling argon 118 gas with a syringe through the septum caps on the vials. The vials were then incubated in an oil bath 119 with increasing temperatures (45°C, 55°C, 65°C, 75°C, 85°C) for 1 h intervals and at 90 °C and 120 100°C for 20 min intervals.

121 2.2 Preparation of surface coatings: The impact of the surface functionalities and their relative 122 ratios on blood responses was studied by incubation vials with surface coatings. The materials 123 prepared as described above were dissolved in acetone to give a 5 % (w/v) solution. The solutions 124 were coated on the internal surface of glass vials (4 mL, 15x45 mm; Waters, Australia) by a 125 solvent-evaporation technique²⁵. Solutions of 1.5 mL were added to the vials and dried in an oven at 126 50 °C until complete evaporation of acetone. The procedure was repeated three times to ensure full 127 coverage on the glass surfaces. After drying, the coated vials were capped at room temperature until

128 used.

For water contact angle measurement, glass coverslips (No. 1, diameter 13 mm, ProSciTech, Australia) were used to provide a flat surface. Coverslips were placed at the bottom of glass vials before the addition of solution and drying step. Uncoated glass vials or coverslips were used as controls.

133 2.3 Characterisation of surface: To analyse the surface properties of the coating, the coated vials or 134 coverslips were cut manually. The functionalization of coatings was analysed by X-ray photoelectron 135 spectroscopy (XPS) (Centre for Microscopy and Microanalysis, University of Queensland). A 136 spectrometer (Axis ULTRA Kratos Analytical, Shimadzu, UK) equipped with a monochromatic Al Ka 137 X-rays (1486.6eV) was operated at 150 W and incident at 45 ° to the sample surface. Photoelectrons emitted from the surface were collected at a take-off angle of theta 90 ° with a 165 mm hemispherical 138 139 electron energy analyser. Elements present in the surface were identified by survey scans taken at pass 140 energy of 160 eV and at resolution of 1.0 eV. These scans recorded binding energies of the 141 photoelectrons ranging from 0 - 1200 eV. Multiplex scans at pass energy of 20 eV and at a higher 142 resolution of 0.05 eV were also performed to determine the chemical states of carbon atoms. The base pressure in the chamber was 1.0×10^{-8} torr during analysis. 143

144 The carbon 1s (C1s) high resolution spectra were processed to determine the relative oxidation states of 145 carbon atoms. Curve fitting of the spectra was performed using the Casa XPS software (version 2.3.14) 146 and a linear baseline with Kratos library Relative Sensitivity Factors (RSFs). The binding energies that 147 are indicated by peaks in spectra were referenced to the C1s aliphatic carbon peak at 285.0 eV. This 148 corrected the effect of surface charging during analysis on shifting the peak positions. Peak areas were 149 normalised and adjusted to obtain a full width at half maximum between 0.9 and 1.1 eV. By 150 determining the area ratios of carbonyl (C-O) component derived from methacrylate monomer, and 151 carboxyl (O-C=O) component derived from both types of comonomers, the compositions of 152 corresponding surface functionalities were obtained. Average data were collected from three

Journal of Materials Chemistry B Accepted Manuscript

153 measurements of each surface. Surface hydrophobicity of coatings were assessed by measuring 154 advancing water contact angle using a FTÅ 200 system (First Ten Ångstroms, Poly-Instruments Pty. 155 Ltd., Australia). Drop shape analysis software (Fta32 version 2.0) was used and data were the average of 156 at least six regions of each surface. Surface morphology of coatings on glass vials were examined by 157 scanning electron microscopy (SEM) with a Quanta 200 scanning electron microscope (FEI, USA) (at a 158 magnification of 25000 x). The roughness of surface coating was measured by atomic force microscopy 159 (AFM) using a Solver P47 Pro scanning probe microscope (NT-MDT Co., Russia). Sample surfaces 160 were scanned in contact mode (constant force) with a golden silicon probe (CSG 11 No. 2 rectangular, 161 NT-MDT Co.). NT-MDT Image Analysis software (version 2.2.0) was used to obtain mean of at least 162 six regions of each surface.

163 2.4 Blood sampling and in vitro incubation: Whole blood was collected from a healthy volunteer who 164 was not on any medication for at least 10 days and with no history of coagulation disorders. 165 Venipuncture was performed by a phlebotomist. Venous blood was drawn into syringes with a 19-166 gauge needle and immediately transferred (1.5 mL) to the vials and incubated at 37 °C. After the desired 167 incubation time, all blood contents in the vials were collected and processed for following experiments. 168 This procedure was approved by the Human Ethics Committee of the Queensland University of 169 Technology. Informed consent was also obtained from donor prior to blood collection.

170 2.5 In vitro coagulation activation: Activation of the coagulation cascade leads to the conversion of 171 prothrombin into active thrombin, a process accompanied with the production of prothrombin fragment 172 1+2 (F1+2). To assess *in vitro* coagulation activation on the coated surfaces, prothrombin F1+2 was 173 analysed using an enzyme-linked immunosorbent assay (ELISA, Enzygnost® F1+2; Dade Behring 174 Marburg GmbH, Germany). Based on our preliminary studies, the coagulation was analysed after 30 175 min of whole blood incubation as the formation of F1+2 demonstrated well established differences 176 among surfaces. Serum was isolated by transferring samples from incubation vials to microcentrifuge 177 tubes containing tri-sodium citrate (0.11 mol/L) (one part of tri-sodium citrate with 9 parts of blood 178 sample) and centrifuged according to the manufacturer's protocols. Plasma levels of F1+2 serve as a baseline and were obtained by centrifuging blood in Vacuette® test tubes containing sodium citrate (3.5
mL blue capped, Greiner Labortechnik, Austria). All data were obtained from 6 replicates of each
surface.

182 2.6 In vitro complement activation: Initiation of the complement system leads to the formation of a 183 common end product C5a convertase, which cleaves complement protein C5 to C5a. C5a is rapidly 184 transformed to C5a-des Arginine (C5a-desArg) by endogenous carboxypeptidase N enzyme in plasma 185 or serum. To determine the extent of complement activation on material-coated surfaces, serum C5adesArg was quantified with Human C5a ELISA Kit II (OptEIATM; BD Bioscience, USA). Serum 186 187 collected from blood samples after 2 h incubation was analysed as the formation of C5a-desArg were 188 detectable and more pronounced based on our preliminary study, which also agrees with earlier findings²⁶. The sandwich ELISA assay was performed as manufacturer's instruction. A background 189 190 level of complement activation monitored as plasma level of C5a-desArg was obtained by centrifuging blood in Vacuette® test tubes containing EDTA (4.0 mL purple capped, Greiner Labortechnik, Austria). 191 192 All data were obtained from 6 replicates of each surface.

193 2.7 Characterisation of clots formed on material-coated surfaces

194 Examination of clot structure: To study whether clot architecture was altered by surfaces presenting 195 various compositions of functional groups, the clots formed in incubation vials were examined by SEM. 196 After 2 h incubation, the clots were fixed with 4% paraformaldehyde (pH 7.4) at 4 °C overnight. The 197 clots were washed twice with phosphate buffered saline (PBS, pH 7.4) for 30 min, and dehydrated in 198 grades of ethanol (50 %, 70 % and 100 %) for 1 h per grade. A longitudinal cut was performed on the 199 clots to allow examination of the ultrastructures at clot/material interface and the centre of the clot. 200 Following dehydration, the clots were processed through 100 % amyl acetate twice of 15 min intervals 201 and dried in a CO₂ critical point dryer. The clots were then mounted, gold-coated and examined with the 202 SEM microscope. Representative images were captured.

203 2.8 Fibrin thickness measurement: The effect of material surfaces on fibrin formation in the clots was
 204 assessed by measuring the diameter of fibrin strand from SEM images at 5000 x magnification. The

measurement was performed using Image J software (version 1.43). A transverse line was drawn perpendicular to long axis of the fibre with clearly defined margins. The pixel value was related to that obtained for the scale bar on the image. At least forty different fibrin strands were measured at random fields approximate 50 µm away from the edge of clot and in the centre of the clot. A minimum of two images were analysed for each sample. The diameter of individual fibrin of each sample was reported as an average for all fibres measured.

211 2.9 Fibrin density measurement: Quantitative fibrin network analysis was performed using Image J 212 software (version 1.43) using a modified method of Undas *et al.*²⁷. A 64-field grid was generated to 213 cover each SEM image and at least twenty fields were selected randomly at the edge and in the centre of 214 the clots. The density of fibrin fibre was determined by counting the number of fibres per field (40 μ m²) 215 and the mean value was presented.

216 2.10 Clot lysis assay: Clot lysis strongly correlates with fibrin thickness and density. The effect of 217 material surfaces on overall clot degradability was investigated and its relationship to the fibrin 218 architecture as determined above was studied. Clot lysis was evaluated by the generation of fibrin 219 degradation product (D-dimer) when the cross-linked clots were digested by fibrinolytic enzymes *in* 220 *vitro*.

A suspended clot system modified from the protocols of Collet *et al.*¹⁴ was used in this study. Whole 221 222 blood was incubated (1.5 mL) in the vials for 2 h at 37 °C to allow complete clot formation and 223 retraction. The clots were removed carefully from the vials and suspended in 3 mL of PBS containing 224 human plasminogen (Glu-plasminogen, 5.4 µg/mL final concentration; American Diagnostica Inc., USA)²⁸. Lysis of the clot was induced by adding recombinant tissue-type plasminogen activator (tPA, 225 226 0.25 µg/mL final concentration; American Diagnostica Inc., USA) at 37 °C with gentle agitation. This 227 concentration of tPA was determined as the lowest one able to induce clot lysis as determined in 228 preliminary study (data not shown). Aliquots of 300 µL were removed at timed intervals and 229 centrifuged at 1000 g for 3 min. The supernatants were stored at -70 °C before analysis. The same 230 volume of PBS was supplemented after samplings. The extent of clot lysis was monitored by measuring the amounts of D-dimer released from the clots using IMUCLONE® D-Dimer ELISA (American Diagnostica Inc., USA). Clots that were suspended in PBS only were used as control of spontaneous fibrinolysis. Weight loss of clots during lysis was also traced during the experiments. All data was obtained from triplicate of clots formed on each surface.

235 2.11 Quantification of growth factors: The release of platelet-derived growth factor-AB (PDGF-AB) 236 and transforming growth factor- β 1 (TGF- β 1) during both clot formation and clot lysis was assayed by 237 ELISA. After 2 h incubation, supernatant serum above the clots was collected and the clots were 238 directly subject to clot lysis as described previously. Supernatant serum and buffer aliquots collected at 239 varied intervals were centrifuged for 15 min at 1000 g and assayed according to the manufacturer's 240 instructions. All Quantikine® ELISA kits were purchased from R&D Systems (Minnesota, USA) and 241 the sandwich ELISA assay was performed. To detect the circulating levels of growth factors, platelet-242 poor plasma was prepared by centrifuging blood in Vacuette® test tubes containing EDTA for 15 min 243 at 1000 g and subsequently for 10 min at 10,000g (4.0 mL purple capped, Greiner Labortechnik, 244 Austria). All data were obtained from triplicates of clots formed on each surface.

245 2.12 Statistical analysis: Data from the experiments were expressed as the mean values \pm standard 246 deviation. Analysis was performed using SigmaPlot (version 11.0; Systat software Inc). The data from 247 control and test surface were compared using the Student's *t*-test. For multiple comparisons, one-way 248 analysis of variance (ANOVA) was used with the Holm-Sidak's test. The significance level was set at p 249 ≤ 0.05 .

250

251 3. Results

3.1 Synthesis and characterisation of biomaterials coated on the surface of vials – Spectra,
hydrophobicity and roughness

The surfaces containing materials of AA and MMA/EMA/BMA are named according to the mole fractions of AA (45, 55, 65%), for instance 45% AA/ 55% MMA as 45 MMA etc. Materials of a single component (i.e homopolymers: PAA, PMMA, PEMA, and PBMA) served as references.

277

278

279

280

281

Journal of Materials Chemistry B Accepted Manuscript $(p \le 0.001)$. Similarly, at the same –COOH ratios, a significantly higher contact angle was observed on surfaces with –(CH₂)₃CH₃ groups compared to those with –CH₃ and –CH₂CH₃ groups (i.e. At an average 33% –COOH from X_{COOH} material of 0.55, p=0.005; At an average 40% –COOH from X_{COOH} material of 0.65, p \leq 0.001). On the other hand, an increase in –COOH ratio (0% to 41%) on -COOH/-(CH₂)₃CH₃ surfaces led to a decrease in contact angle. This indicated that surface

257 Materials including 45BMA (containing 25% –COOH); 55MMA, 55EMA & 55BMA (containing 258 33% –COOH) and 65MMA, 65EMA & 65BMA (containing 40% –COOH) were used in this study. 259 The synthesised materials were coated into vials and characterised to ensure the correct ratios of 260 carboxyl and alkyl groups were achieved. Spectra by X-ray photoelectron spectroscopy (XPS) of 261 surfaces were shown in Figure 1a-d. C1s spectra demonstrated alkyl methacrylates differ from 262 acrylic acid by a prominent peak corresponding to carbon component C-O (286.8 eV), whereas both 263 comonomers showed three common components: C-C (285.0 eV), C-COO (285.7 eV), and O-C=O 264 (289.1 eV) (Figure1e-g). The relative compositions of C-O and O-C=O on surface coatings were 265 measured from the peak areas. The surface ratios of -COOH/-CH₃, -CH₂CH₃ or (CH₂)₃CH₃ are 266 summarised in **Table 1**. As clearly demonstrated by BMA surfaces, the surface coatings became 267 increasingly richer in -COOH group (i.e. increased X_{COOH} coating) with the increase in the AA 268 monomer feed (i.e. increased X_{COOH} material). Interestingly, X_{COOH} material of 0.45 and 0.55 at 269 MMA and EMA surfaces showed similar X_{COOH} coating concentrations (i.e. 0.32 - 0.34). Also, 270 X_{COOH} coating at MMA, EMA and BMA surfaces were found to be comparable at X_{COOH} material 271 of 0.55 (0.33, 0.32 & 0.34 respectively), and of 0.65 (0.41, 0.39 & 0.41 respectively). 272 The advancing water contact angle of an uncoated glass substrate was 54.1 ± 4.2 °. With addition of a coating, the values increased to $77.6 \pm 3.1^{\circ}$, $82.9 \pm 1.0^{\circ}$ and $91.8 \pm 4.4^{\circ}$ for PMMA, PEMA and 273 PBMA, respectively (**Table 2**). These results were in agreement with published data ²⁹. The contact 274 275 angle values of homopolymer-derived coatings increased significantly in the order: $-CH_3 < -$ 276 $CH_2CH_3 < -(CH_2)_3CH_3$, suggesting the surface hydrophobicity increased with the alkyl chain length

282 hydrophobicity was strongly influenced by the functional groups and their ratios. 283 Scanning electron microscopy (SEM) and atomic force microscopy (AFM) showed that all coated

surfaces exhibited as smooth as the uncoated surfaces (data not shown).

3.2 Effects on coagulation responses

286 The serum level of prothrombin F1+2 after 30 min incubation was shown in Figure 2a. All material-287 coated surfaces had higher levels than the plasma (0.014 ± 0.0007 %, i.e. 0.06 ± 0.003 nmol/L) but 288 lower levels compared to the uncoated glass surfaces (p < 0.001). In general, BMA surfaces induced 289 significantly higher F1+2 level than MMA and EMA surfaces, regardless of the –COOH ratios ($p \leq$ 290 0.001). Amongst BMA surfaces with various –COOH ratios, 55BMA had a slightly higher F1+2 level 291 compared to 45BMA and 65BMA but no significant difference was detected (p = 0.305). Among 292 55MMA, 55EMA & 55BMA surfaces with approximately 33% –COOH, 55BMA showed the highest 293 F1+2 level whereas 55EMA showed the lowest level ($p \le 0.001$). A similar effect of alkyl groups on 294 coagulation activation was also found on surfaces with a higher content of -COOH (i.e. 40% on 295 65MMA, 65EMA & 65BMA) ($p \le 0.001$). In contrast to BMA surfaces, an increase in –COOH ratio on 296 MMA and EMA surfaces reduced F1+2 level significantly ($p \le 0.001$).

3.3 Effect on complement response

The serum level of C5a-desArg after 2 h incubation was shown in **Figure 2b**. All material-coated surfaces had dramatically reduced level compared with the uncoated glass surfaces, though expectedly higher than the plasma level ($6 \pm 1\%$, i.e. 7 ± 1 ng/mL) ($p \le 0.001$). Similar to the trends observed for coagulation activation, BMA surfaces generally had higher C5a-desArg level than MMA and EMA surfaces ($p \le 0.001$). Among BMA surfaces, 55BMA had a significantly lower level than 45BMA and 65BMA ($p \le 0.001$). No difference was found between the latter two surfaces.

For surfaces with approximately 33% –COOH (55MMA, 55EMA & 55BMA), and 40% –COOH (65MMA, 65EMA & 65BMA), a lower C5a-desArg level was found on EMA surface for both percentages ($p \le 0.001$). An increase in –COOH ratio on MMA and EMA surfaces also further reduced C5a-desArg level (p = 0.036; p = 0.04, respectively). The lowest C5a-desArg level among all coated surfaces was on the 65EMA surface. Overall, the extent of complement activation was significantly

310 Increasing –COOH ratio on the surfaces with – CH_3 and – CH_2CH_3 groups further reduced complement

311 response.

312 **3.4 Effect on clot morphology and structure**

313 The effect of various ratios of surface –COOH groups on clot structure was shown by 45BMA, 55BMA 314 and 65BMA. As shown in Figure 3a-d, the edge of clots formed on BMA surfaces showed thicker 315 fibrin fibers at a denser network. In contrast, the edge of clots formed on uncoated glass surfaces 316 showed thinner fibers at a loose network. The fibrin at the edge of clots on glass surfaces were 317 significantly smaller in diameter (Figure 3i) and lower in density (Figure 3k) than those of BMA 318 surfaces ($p \le 0.001$). Among BMA surfaces, the fibrin diameter at the edge of clots was significantly 319 smaller on 55BMA, while the fibrin density was significantly lower on 45BMA ($p \le 0.001$). No 320 difference in fibrin density at the edge was found between 55BMA and 65BMA (p = 0.237). In 321 addition, fibrin architecture was found to change dramatically from the edge to the centre of the clot 322 (Figure 3e-h). In the centre of clots, the fibrin of all surfaces except 45BMA increased in diameter 323 (Figure 3), while the densities of all surfaces decreased approximately 3 to 5 times ($p \le 0.001$) (Figure 324 **31**).45BMA produced significantly thinner fibres ($p \le 0.05$) at higher density ($p \le 0.001$) than all other 325 surfaces. Overall variation of the -COOH ratio on -(CH₂)₃CH₃ bearing surfaces led to significant 326 changes in the fibrin thickness and network density.

The effect of surface alkyl groups on clot structures was illustrated by 65MMA, 65EMA & 65BMA. The clots formed on surfaces with approximately 40% –COOH (65MMA, 65EMA & 65BMA) and uncoated glass surfaces were observed in Figure 4a-d. Compared to the uncoated glass surfaces, the fibrin fibres at the edge of clots formed on 65MMA, 65EMA and 65BMA were significantly larger in diameter and higher in density ($p \le 0.001$) (Figure 4i, k). Among 65MMA, 65EMA and 65BMA surfaces, the fibrin diameter at the edge of the clots of 65BMA was significantly larger than the others ($p \le 0.001$). No difference was found between those of 65MMA and 65EMA (p = 0.287). Moreover, the fibrin density was significantly higher on 65MMA while

335 lower on 65EMA ($p \le 0.001$).

336 Compared to the fibres at the edge, the fibres at the centre of the clots on all surfaces except 65EMA 337 increased in diameter (Figure 4), and the fibrin densities of all surfaces decreased approximately 5 338 times ($p \le 0.001$) (Figure 4I). While the fibrin diameter of 65EMA was significantly smaller than those 339 of 65MMA and 65BMA ($p \le 0.001$), no significant differences were found between the latter (p =340 0.105). For the fibrin density at the centre of the clots, it was significantly higher on 65MMA than all 341 the others ($p \le 0.001$). Although the mean fibrin densities of 65EMA and 65BMA were not significant 342 different, a similar trend in fibrin density was observed at the edge and at the centre of clots formed on 343 65MMA, 65EMA and 65BMA.

344 **3.5 Effect on fibrinolysis**

345 To evaluate the effect of various ratios of surface –COOH groups on fibrinolysis, D-dimer levels 346 from the clots of 45BMA, 55BMA and 65BMA were compared. After 1 h of lysis, all BMA 347 surfaces revealed significant decrease D-dimer levels compared to uncoated glass surfaces (Figure 348 5a), suggesting the clots of BMA surfaces initially underwent a slower rate of fibrinolysis. In 349 addition, 55BMA led to a faster fibrinolysis whereas 65BMA led to a slower rate. Consistent with 1 350 h of lysis, the mean D-dimer level of 55BMA progressively increased compared to the other BMA 351 surfaces over the rest of lysis period, with a significant difference detected after 8 h of lysis (p \leq 352 (0.05) (Figure 5c). Taken together, BMA surfaces displayed a delayed onset of fibrinolysis during 353 the first hour of lysis compared to the uncoated glass surfaces.

To evaluate the effect of surface alkyl groups on fibrinolysis, the clots of surfaces exhibiting 40% – COOH (65MMA, 65EMA & 65BMA) were compared. In accordance to BMA surfaces, 65MMA, 65EMA and 65BMA surfaces showed a significant slower fibrinolysis than uncoated glass surfaces after 1 h of lysis (Figure 5b). Among the coated surfaces, 65MMA showed a significantly slower fibrinolysis whereas 65EMA showed a faster rate. No significant differences were found for the rest of the lysis period (Figure 5d).

As evident from uncoated glass surfaces (Figure 5e), the control clots subjected to PBS buffer only showed a negligible amount of D-dimer as to the plasma level ($0.06 \pm 0.005 \ \mu g/mL$ to 2.8 ± 0.287 $\mu g/mL$ from 1 h to 24 h after lysis) when compared to the clots exposed to tPA and plasminogen in PBS buffer. This suggested that the spontaneous fibrinolysis was not profound and our suspended clot system supplemented with fibrinolytic enzymes was feasible for assaying clot lysis.

365 3.6 Effect on PDGF-AB and TGF-β1 release

The release of PDGF-AB and TGF- β 1 in supernatant serum after clot formation on 65MMA, 65EMA and 65BMA surfaces was shown in **Figure 6**. Significantly elevated PDGF-AB (**Figure 6a**) and TGF- β 1 (**Figure 6b**) levels were found on all surfaces compared to plasma baseline (308 ± 49 pg/mL for PDGF-AB and 1021 ± 31 pg/mL for TGF- β 1). This confirmed the growth factors are released upon clot formation. Among 65MMA, 65EMA & 65BMA surfaces, 65MMA showed a significantly higher PDGF-AB level compared to 65EMA (p ≤ 0.05). For TGF- β 1, however, we found no significant differences among coated and uncoated surfaces.

The release of growth factors in the buffer during clot lysis was also assessed. The degrading clots of 65MMA, 65EMA and 65BMA showed a similar release pattern of PDGF-AB with a peak at 8 h of lysis. Overall 65MMA led to a significantly higher PDGF-AB level at 1 h ($p \le 0.001$) and 4 h ($p \le 0.05$) after lysis (**Figure 6c**). Unlike PDGF-AB, the release of TGF- β 1 gradually increased over the course of lysis (**Figure 6d**). With a similar pattern of release, 65BMA led to a significantly higher TGF- β 1 level than 65EMA at 1 h and 4 h of lysis ($p \le 0.05$) (**Figure 6d**). In summary, both PDGF-AB and TGF- β 1 were released at higher amounts during clot formation than during clot lysis.

380

381 4. Discussion

In this study we investigated whether blood response and blood clot formation could be modulated on the coating surface of artificial bone implants through surface chemical functionalities and their compositions. Our strategy of presenting surface functionalities $-COOH/-CH_3$, $-CH_2CH_3$ or -(CH₂)₃CH₃) at different compositions was accomplished by varying AA/MMA, EMA or BMA at 386 different mole fractions in forming the materials. Our results showed that the inner surface of 387 incubation vial was modified effectively by the material coating. Such a surface coating is a 388 common and efficient way to modify implants having complex geometries without altering the bulk properties³⁰. We found that an increase in AA proportion generally increased the surface content of 389 390 -COOH groups but the content of -COOH groups was lower than the expected AA fraction. 391 Similar observations were found in other studies and might be attributed to different degrees of copolymerisation in related to monomer reactivity ratios³¹, polymer chain mobilities of PAA and 392 393 poly(alkyl methacrylates) in subsurface layer which is beyond sampling depth (<10 nm) of XPS, as well as reorientation of hydrophilic functional group to avoid air exposure³². 394

395 Our results demonstrated that surface hydrophobicity of coated surfaces correlates well with the chemical compositions, as in accordance to the literature^{33, 34}. At relatively the same –COOH ratios, 396 397 surfaces presenting $-(CH_2)_3CH_3$ groups exhibited a higher hydrophobicity than $-CH_3$ and -398 CH₂CH₃ groups whereas the latter two did not differ significantly. This suggests that the difference 399 in one-carbon length between $-CH_3$ and $-CH_2CH_3$ groups has limited impact on modulating surface hydrophobicity in the presence of -COOH groups. In fact, both the nature of functional groups and 400 their relative compositions are the key factors in controlling surface hydrophobicity³⁵. In contrast, 401 402 there is no evident relationship between surface roughness and surface functional groups and their 403 ratios.

404 It was showed that surface functional groups and their compositions strongly influence the rate of 405 coagulation activation. Increasing -COOH ratios (from 33% to 40%) on surfaces with -COOH/-406 CH_3 and $-CH_2CH_3$ decrease the rate of the activation. This finding is surprising since the initiation 407 of intrinsic pathway on -COOH/-CH₃ SAM surfaces has been shown to increase with increasing -COOH ratio^{19, 36}. Previous studies also demonstrated that FXII activation of intrinsic pathway is 408 directly dependent on the amount of negatively charged functional groups^{37, 38}. Indeed, Sperling *et* 409 al. ¹⁹found that -COOH/-CH₃ SAM surfaces with less than 50% -COOH did not show FXIIa 410 411 activity in plasma phase. Rather, these surfaces had a noticeable effect on activating FXII adsorbed

412

413

414

415

416

417

418

Journal of Materials Chemistry B

on the surfaces. In addition, activated platelets were reported to trigger FXII activation on their surfaces and induce FXIIa-mediated intrinsic activation ^{39, 40}. However, platelet adhesion and activation have been shown to decrease with increasing –COOH content on –COOH/–CH₃ surfaces[29,30]. Given that interplay between FXIIa initiation and activated platelets propagation is crucial for a substantial coagulation response; a decline of platelet-dependent amplification of coagulation may explain our finding of an alteration of the rate of activation at 30 min. In addition, our results showed that the surface alkyl groups have specific effects on the rate of coagulation initiation. Regardless of varied –COOH ratios, the surfaces with –(CH₂)₃CH₃) groups

419 coagulation initiation. Regardless of varied -COOH ratios, the surfaces with $-(CH_2)_3CH_3$ groups 420 induced a faster rate of activation than $-CH_3$ and $-CH_2CH_3$ groups, and that varying -COOH ratios 421 on $-(CH_2)_3CH_3$ bearing surfaces was less likely to affect the kinetic of coagulation. Hydrophobic 422 materials were generally found to increase adsorption and conformational change of fibrinogen, 423 which is proposed to be mediated by the strong hydrophobic interaction between D-domain of 424 fibringen and the substrate, leading to stronger platelet adhesion and activation when compared to hydrophilic materials⁴¹. These observations are in line with earlier finding that more hydrophobic – 425 (CH₂)₃CH₃) groups on a polymer surface yielded the highest fibrinogen adsorption, platelet 426 427 activation and faster rate of coagulation activation compared to -CH₃ and -OH groups⁴². 428 Accordingly, the weak electrostatic force between α C-domain of fibrinogen and negatively charged 429 -COOH groups may also explain the minor effect of varying -COOH ratios in the presence of -430 (CH₂)₃CH₃) groups on the kinetic of coagulation, unlike seen on -CH₃ and -CH₂CH₃ bearing 431 surfaces. Interestingly, between two less hydrophobic $-CH_3$ and $-CH_2CH_3$ groups, the $-CH_3$ group 432 displayed a specific activity in inducing a faster rate of coagulation initiation. As the surfaces with 433 these two alkyl groups did not show a significant difference in water contact angles at the same – 434 COOH ratios, this finding suggests that the surface hydrophobicity (surface free energy) is not the sole factor that governs blood coagulation response. Sivaraman et al. ⁴³convincingly demonstrated 435 436 that -COOH and -OH SAMs with similar levels of surface hydrophilicity induced a significant 437 difference in the degree of structural change of adsorbed fibrinogen and albumin. Since surface

hydrophobicity is actually determined by the surface chemical species, the characteristics of thesurface functionalities would play a more significant role in modulating coagulation activation.

440 Analysis of complement activation showed that all material-coated surfaces remarkably reduced the 441 response compared to uncoated surfaces, indicating these surfaces had a weaker immunogenic 442 property. In addition, we found that the complement response followed an entirely similar pattern of 443 surface-activated coagulation. The high interdependence between complement and coagulation 444 activation on material surfaces confirms our whole blood incubation system allows free cross-talk between both cascades to take place as it is found *in vivo*^{44, 45}. More importantly, our data show 445 446 unambiguously that surface functional groups and their relative ratios have a synergistic effect on 447 modulating the activation of both cascades. The complement response on material surfaces was 448 significantly reduced with the alkyl length in the order: $-(CH_2)_3CH_3 > -CH_3 > -CH_2CH_3$. Berglin et al.²⁰suggested that complement activation is reduced with increased alkyl chain length of poly 449 450 (alkyl methacrylates) ranged from 4 to 18 carbons. However, similar to our findings, they also 451 found that PMMA with $-CH_3$ induces slightly less activation than PIBMA (poly (isobuty) 452 methacrylate) with $-(CH_2)_3CH_3$, of which the complement activity did not differ from that of 453 PBMA.

454 Examination of resultant blood clots showed that the material-coated surface modulated the fibrin 455 architecture resulting in a thicker fibre at denser network at the clot exterior when compared to 456 uncoated glass surfaces. The elevated levels of prothrombin F1+2 on uncoated glass and 55BMA 457 surfaces produced clots with much thinner fibres when compared to material-coated surfaces and BMA surfaces, respectively. These findings are consistent with the work of Wolberg et al. ⁴⁶in 458 459 which elevated prothrombin level triggers the formation of thinner fibrin due to increased initial 460 rate, peak and total amount of thrombin generation. In addition, the clot interior showed dramatic 461 changes in fibrin architectures from the exterior for all surfaces in which fibrin were thicker and at 462 very loose network. Moreover, we found a consistent trend on fibrin density at the clot exterior and 463 interior on surfaces containing same –COOH ratio but different alkyl groups. This indicates that the

464 surface functionalities and relative ratios have a specific influence on fibrin structuredensity465 throughout the clots.

To verify *in vivo* stability of the altered clot structure which is important for physical support at the injured sites and subsequent new bone ingrowth, we measured the rate of clot lysis using a suspended clot system. Our results demonstrated that all material-coated surfaces led to a significantly slower fibrinolysis in the first hour of lysis compared to the uncoated glass surfaces. This slower onset of fibrinolysis is in good agreement with the tight network and thicker fibrin observed on the clot exterior on coated surfaces, in accordance with literatures which indicated that fibrinolysis occurs predominantly faster on loose network and thinner fibrin⁴⁷.

473 To assess biological function of the altered clots for enhancing bone regeneration, we measured the 474 clot releases of PDGF-AB and TGF- β 1. It has been well documented that various growth factors are expressed in different phases of bone healing⁴⁸. In particular, the initiation of bone regeneration is 475 476 suggested to begin with the release of PDGF-AB and TGF-β1 after a clot is formed⁴⁹. PDGF-AB is 477 most abundant in platelet α -granules and is known to support chemotaxis and proliferation of 478 fibroblasts, smooth muscle cells as well as endothelial cells, resulting in collagen synthesis and 479 angiogenesis⁵⁰. On the other hand, TGF- β 1 is predominant in platelets, bone and cartilage. It is 480 shown to serve as a mitogen for osteoblasts, fibroblasts and endothelial cells, as well as an inhibitor of osteoclasts^{51, 52}. In addition, both PDGF-AB and TGF-β1 are chemotactic for inflammatory cells 481 482 such as neutrophils, monocytes or macrophages, which establishes a positive feedback loop of growth factors within the injured bone⁵³. In view of their function in supporting bone healing, we 483 484 evaluated the potentials of modifications in fibrin structure and fibrin structure-dependent 485 fibrinolysis on affecting the release of these growth factors from the intact and degrading clots.

486 Altogether, this work opens the new scope of blood clots generated on various surface 487 functionalities for treating severe bone injuries. Our studies on the effect of surface chemistry on 488 blood clots were initiated based on the notion that the normal mechanism of bone healing could be 489 useful for enhancing the healing microenvironment in the presence of synthetic bone implants.

490 **5.** Conclusions

To our best knowledge, this is the first study which provides a comprehensive picture of how surface functional groups and their concentrations considerably modulate blood cascade activation in the context of whole blood clot formation; subsequent fibrin architecture, susceptibility to fibrinolysis and release of growth factors. The knowledge generated herein would allow a prior prediction of the whole blood response directly from the material formulation. These results explore the future potential of applying blood clot regulation by various material coatings to improve the efficacy of synthetic bone grafts.

498

499

500	
501	
502	Acknowledgements
503	We thank Dr Barry Wood of UQ for his support with X-ray photoelectron microscopy and Associate
504	Professor Nunzio Motta for assisting with atomic force microscopy. The financial support from IHBI
505	and the Queensland University of Technology is also gratefully acknowledged.
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	
522	
523	
524	
525	
526	

527528 Legends:

529

530 **Figure 1.** XPS survey spectra of a) uncoated glass, b) PAA, c) PBMA, and d) 45BMA (45%

531 AA/BMA) coated surfaces. XPS C1s spectra of e) PAA, f) PMMA, and g) 45MMA coated surfaces.
532

Figure 2. The serum levels of a) prothrombin F1+2, b) C5a-desArg, after whole blood incubation with material-coated surfaces relative to the uncoated glass surfaces (%). Plasma levels served as baseline. Data was presented as mean of six replicates of each surface with SD. * $p \le 0.001$

536

537 Figure 3. Scanning electron microscopy analysis of whole blood clot structures formed on 45BMA, 538 55BMA, 65BMA and uncoated glass surfaces. Micrographs of the edge of clots (top panel; a-d) and 539 the centre of clots (bottom panel; e-h), scale bar represents 20 µm. Comparison of fibrin thickness 540 (diameter; nm) i) at the edge; j) at the centre of clots. Comparison of fibrin density (fibre number 541 per 40 μ m²) k) at the edge; l) at the centre of clots. Data of fibrin thickness was presented as mean 542 of at least 40 fibrin fibres measured at random field while data of fibrin density was presented as mean of fibre numbers quantified in at least 20 random areas of 40 μ m² at the edge and at the centre 543 544 of the clots of each surface with SD.* $p \le 0.001$.

545

546 Figure 4. Scanning electron microscopy analysis of structure of clots formed on 65MMA, 65EMA, 547 65BMA and uncoated glass surfaces. SEM micrographs of the edge of clot (top panel; a-d) and the 548 centre of clot (bottom panel; e-h), scale bar represents 20 µm. Comparison of fibrin diameter (nm) i) at the edge; j) at the centre of clots. Comparison of fibrin density (fibre number per 40 μ m²) k) at 549 550 the edge; 1) at the centre of clots. Data of fibrin thickness was presented as mean of at least 40 fibrin 551 fibres measured at random field while data of fibrin density was presented as mean of fibre numbers quantified in at least 20 random areas of 40 μ m² at the edge and at the centre of the clots of each 552 553 surface with SD.* $p \le 0.001$.

Figure 5. Release of D-dimer during clot lysis. The D-dimer levels of clots on BMA surfaces a) after 1 h compared to uncoated glass surfaces, and c) over 24 h of lysis. The D-dimer levels of clots on 65MMA, 65EMA and 65BMA surfaces b) after 1 h compared to uncoated glass surfaces, and d) over 24 h of lysis. e) The D-dimer levels over 24 h-lysis period of uncoated glass surfaces and relative control clots subject to PBS only.

560

Figrue 6. The serum levels of a) PDGF-AB and b) TGF- β 1 after 2 h of whole blood incubation with 65MMA, 65EMA and 65BMA surfaces compared to the uncoated glass surfaces and the plasma baseline. *In vitro* releases of c) PDGF-AB and d) TGF- β 1 during lysis of clots formed on 65MMA, 65EMA and 65BMA surfaces. Data was presented as mean of triplicates of each surface with SD.* p \leq 0.001 ** p \leq 0.05

566

567 **Table 1.** Ratio of –COOH groups measured on surface coatings (X_{COOH} coating) compared to mole 568 fraction of –COOH group-containing AA (X_{COOH} material) composed with MMA, EMA or BMA. 569 Data were presented as the average value of three measurements.

570

571 **Table 2.** Advancing contact angles of surfaces coated with materials composed of varied mole 572 fraction of AA (X_{COOH} material) with MMA, EMA or BMA. Measurements were reported as the 573 average value of contact angles of at least six data points.

574

575

576 577

577 **Reference**

578	1.	Y. Xiao, H. Qian, W. G. Young and P. M. Bartold, <i>Tissue Eng</i> , 2003, 9, 1167-1177.
579	2.	P. M. Bartold, Y. Xiao, S. P. Lyngstaadas, M. L. Paine and M. L. Snead, Periodontology
580		2000, 2006, 41, 123-135.
581	3.	D. Logeart-Avramoglou, F. Anagnostou, R. Bizios and H. Petite, J Cell Mol Med, 2005, 9,
582		72-84.
583	4.	I. Schleicher, A. Parker, D. Leavesley, R. Crawford, Z. Upton and Y. Xiao, Tissue
584		engineering, 2005, 11, 1688-1698.
585	5.	N. E. Carlson and R. B. Roach, Jr., J Am Dent Assoc, 2002, 133, 1383-1386.
586	6.	Y. Roussy, M. P. Bertrand Duchesne and G. Gagnon, Clin Oral Implants Res, 2007, 18,
587		639-648.
588	7.	J. van den Dolder, R. Mooren, A. P. Vloon, P. J. Stoelinga and J. A. Jansen, Tissue Eng,
589		2006, 12, 3067-3073.
590	8.	G. Weibrich, T. Hansen, W. Kleis, R. Buch and W. E. Hitzler, Bone, 2004, 34, 665-671.
591	9.	M. E. Carr, Jr., E. J. Martin and S. L. Carr, Blood Coagul Fibrinolysis, 2002, 13, 193-197.
592	10.	A. S. Wolberg, <i>Blood Rev</i> , 2007, 21, 131-142.
593	11.	J. P. Collet, H. Shuman, R. E. Ledger, S. Lee and J. W. Weisel, Proc Natl Acad Sci USA,
594		2005, 102, 9133-9137.
595	12.	W. Liu, L. M. Jawerth, E. A. Sparks, M. R. Falvo, R. R. Hantgan, R. Superfine, S. T. Lord
596		and M. Guthold, Science, 2006, 313, 634.
597	13.	D. A. Gabriel, K. Muga and E. M. Boothroyd, J Biol Chem, 1992, 267, 24259-24263.
598	14.	J. P. Collet, J. Soria, M. Mirshahi, M. Hirsch, F. B. Dagonnet, J. Caen and C. Soria, Blood,
599		1993, 82, 2462-2469.
600	15.	J. D. Mills, R. A. Ariens, M. W. Mansfield and P. J. Grant, Circulation, 2002, 106, 1938-
601		1942.
602	16.	J. E. Davies, <i>J Dent Educ</i> , 2003, 67, 932-949.
603	17.	W. E. Oprea, J. M. Karp, M. M. Hosseini and J. E. Davies, <i>J Craniofac Surg</i> , 2003, 14, 292-
604		300.
605	18.	M. B. Gorbet and M. V. Sefton, <i>Biomaterials</i> , 2004, 25, 5681-5703.
606	19.	C. Sperling, M. Fischer, M. F. Maitz and C. Werner, <i>Biomaterials</i> , 2009, 30, 4447-4456.
607	20.	M. Berglin, M. Andersson, A. Sellborn and H. Elwing, <i>Biomaterials</i> , 2004, 25, 4581-4590.
608	21.	H. B. Lee, G. Khang and J. H. Lee, <i>Biomaterials</i> , 2007, 3-1 - 3-21.
609	22.	M. J. Butler and M. V. Setton, J. Biomed. Mater. Res., Part A, 2007, 82, 265-273.
610	23.	G. A. Hutcheon, C. Messiou, R. M. Wyre, M. C. Davies and S. Downes, <i>Biomaterials</i> , 2001,
611	2.4	22,66/-6/6.
612	24.	X. Yan and K. A. Gemeinnart, J. Controlled Release, 2005, 106, 198-208.
613	25.	S. Fujishita, C. Inaba, T. Ishisaka, M. Gemmei-Ide and H. Kitano, Colloias Surf B Disintenfrance, 2000, 74, 45, 50
014 615	26	Biointerfaces, 2009, 74, 45-50.
013	20.	C. Spering, K. B. Schweiss, U. Strener and C. werner, <i>Biomaterials</i> , 2005, 26, 6547-6557.
010 617	27.	A. Ulidas, K. Szuldizyliski, E. Stepleli, J. Zalewski, J. Goulewski, W. Hacz, M. Pasowicz and V. Zmudka. Athenasclanosis 2009, 106, 551, 557
01/ 619	20	D. T. Opunderson, C. W. Francis and V. I. Marder, <i>LLab Clin Mod</i> 1002, 120, 120, 120
610	20. 20	F. I. Ohuhudaison, C. W. Flancis and V. J. Mardel, <i>J Lub Cun Mea</i> , 1992, 120, 120-126. S. Takamata, T. Vamamata, K. Tauru, S. Hayakawa, A. Osaka and S. Takashima.
620	29.	Biomatorials 2004 25 3485 3492
621	30	7 Ma 7 Mag and C Gao. Colloids Surf B Bigintarfaces 2007 60 137 157
622	30.	E. Mao and C. Gao, Conoias surf D Diomerfuces, 2007, 00, 157-157. K. I. Eknenvong, I.Cham Educ, 1985, 62, 173, 174
622	31.	K. I. Expension, σ Chemical Fducation 1985 62 173-174. K. I. Eknenvong Journal of Chemical Education 1985 62 173-174
624	32.	C Ukiwe A Mansouri and D V Kwok I Colloid Interf Sci 2005 285 760 768
625	3 <u>4</u>	I N Lai B Sunderland I M Xue S Yan W I Zhao M Folkard B D Michael and V
626	J 1.	G Wang Annl Surf Sci 2006 252 3375-3379
040		\mathbf{S} , \mathbf{T} and \mathbf{T} and \mathbf{T} and \mathbf{S} and \mathbf

627	35.	M. Y. Tsai, Y. T. Sun and J. C. Lin, J Colloid Interf Sci, 2007, 308, 474-484.
628	36.	M. Fischer, C. Sperling and C. Werner, J Mater Sci-Mater M, 2010, 21, 931-937.
629	37.	R. Zhuo, C. A. Siedlecki and E. A. Vogler, <i>Biomaterials</i> , 2006, 27, 4325-4332.
630	38.	X. Y. Chen, J. Wang, Z. Paszti, F. L. Wang, J. N. Schrauben, V. V. Tarabara, A. H.
631		Schmaier and Z. Chen, Anal Bioanal Chem, 2007, 388, 65-72.
632	39.	P. E. van der Meijden and J. W. Heemskerk, Expert Rev. Hematol., 2010, 3, 269-272.
633	40.	J. Back, J. Sanchez, G. Elgue, K. N. Ekdahl and B. Nilsson, Biochem. Biophys. Res.
634		<i>Commun.</i> , 2010, 391, 11-17.
635	41.	H. Nygren, Colloid Surface B, 1996, 6, 329-333.
636	42.	C. Sperling, M. F. Maitz, S. Talkenberger, M. F. Gouzy, T. Groth and C. Werner,
637		Biomaterials, 2007, 28, 3617-3625.
638	43.	B. Sivaraman, K. P. Fears and R. A. Latour, Langmuir, 2009, 25, 3050-3056.
639	44.	M. M. Markiewski, B. Nilsson, K. N. Ekdahl, T. E. Mollnes and J. D. Lambris, Trends
640		Immunol, 2007, 28, 184-192.
641	45.	E. I. B. Peerschke, W. Yin and B. Ghebrehiwet, Adv Exp Med Biol, 2008, 632, 81-91.
642	46.	A. S. Wolberg, D. M. Monroe, H. R. Roberts and M. Hoffman, Blood, 2003, 101, 3008-
643		3013.
644	47.	J. L. Mullin, S. E. Norfolk, J. W. Weisel and S. T. Lord, Ann N Y Acad Sci, 2001, 936, 331-
645		334.
646	48.	K. J. Cross and T. A. Mustoe, Surg Clin North Am, 2003, 83, 531-545, vi.
647	49.	A. F. Kells, S. R. Coats, H. S. Schwartz and R. L. Hoover, Connect Tissue Res, 1995, 31,
648		117-124.
649	50.	J. Andrae, R. Gallini and C. Betsholtz, Genes Dev, 2008, 22, 1276-1312.
650	51.	H. Zhang, M. S. Aronow and G. A. Gronowicz, J Biomed Mater Res A, 2005, 75, 98-105.
651	52.	M. Bosetti, F. Boccafoschi, M. Leigheb and M. F. Cannas, <i>Biomol Eng</i> , 2007, 24, 613-618.
652	53.	G. S. Ashcroft, Microbes Infect, 1999, 1, 1275-1282.
653		
654		



Figure 1. XPS survey spectra of a) uncoated glass, b) PAA, c) PBMA, and d) 45BMA (45% AA/BMA) coated surfaces. XPS C1s spectra of e) PAA, f) PMMA, and g) 45MMA coated surfaces. 150x134mm (150 x 150 DPI)



Figure 2. The serum levels of a) prothrombin F1+2, b) C5a-desArg, after whole blood incubation with material-coated surfaces relative to the uncoated glass surfaces (%). Plasma levels served as baseline. Data was presented as mean of six replicates of each surface with SD. * $p \le 0.001$ 213x282mm (96 x 96 DPI)



Figure 3. Scanning electron microscopy analysis of whole blood clot structures formed on 45BMA, 55BMA, 65BMA and uncoated glass surfaces. Micrographs of the edge of clots (top panel; a-d) and the centre of clots (bottom panel; e-h), scale bar represents 20 μ m. Comparison of fibrin thickness (diameter; nm) i) at the edge; j) at the centre of clots. Comparison of fibrin density (fibre number per 40 μ m2) k) at the edge; l) at the centre of clots. Data of fibrin thickness was presented as mean of at least 40 fibrin fibres measured at random field while data of fibrin density was presented as mean of fibre numbers quantified in at least 20 random areas of 40 μ m2 at the edge and at the centre of the clots of each surface with SD.* p \leq 0.001. 448x497mm (96 x 96 DPI)



Figure 4. Scanning electron microscopy analysis of structure of clots formed on 65MMA, 65EMA, 65BMA and uncoated glass surfaces. SEM micrographs of the edge of clot (top panel; a-d) and the centre of clot (bottom panel; e-h), scale bar represents 20 μ m. Comparison of fibrin diameter (nm) i) at the edge; j) at the centre of clots. Comparison of fibrin density (fibre number per 40 μ m2) k) at the edge; l) at the centre of clots. Data of fibrin thickness was presented as mean of at least 40 fibrin fibres measured at random field while data of fibrin density was presented as mean of fibre numbers quantified in at least 20 random areas of 40 μ m2 at the edge and at the centre of the clots of each surface with SD.* p ≤ 0.001. 440x493mm (96 x 96 DPI)



Figure 5. Release of D-dimer during clot lysis. The D-dimer levels of clots on BMA surfaces a) after 1 h compared to uncoated glass surfaces, and c) over 24 h of lysis. The D-dimer levels of clots on 65MMA, 65EMA and 65BMA surfaces b) after 1 h compared to uncoated glass surfaces, and d) over 24 h of lysis. e) The D-dimer levels over 24 h-lysis period of uncoated glass surfaces and relative control clots subject to PBS only.

403x370mm (96 x 96 DPI)





X _{COOH} Materials	X _{COOH} Coating (MMA)	Х _{СООН} Coating (EMA)	X _{COOH} Coating (BMA)
0	0	0	0
0.25	0.20	0.17	0.13
0.45	0.34	0.33	0.25
0.55	0.34	0.32	0.33
0.65	0.41	0.39	0.41

Table 1: The surface ratios of $-COOH/-CH_3$, $-CH_2CH_3$ or $-(CH_2)_3CH_3$

Ratio of -COOH groups measured on surface coatings (X_{COOH} coating) compared to mole fraction of -COOH group-containing AA (X_{COOH} material) composed with MMA, EMA or BMA. Data were presented as the average value of three measurements.

Х _{СООН} сороlymer	MMA	EMA	BMA
0	77.6 ± 3.1	82.9 ± 1.0	91.8 ± 4.4
0.25	74.3 ± 4.3	77.1 ± 2.2	88.3 ± 1.4
0.45	72.4 ± 4.6	74.9 ± 2.6	86.7 ± 1.0
0.55	73.4 ± 8.6	75.1 ± 1.7	84.4 ± 2.3
0.65	71.0 ± 2.7	73.7 ± 3.4	81.1 ± 2.4

Table 2: The advancing contact angle value of coated substrate

Advancing contact angles of surfaces coated with materials composed of varied mole fraction of acrylic acid and alkyl methacrylates. Measurements were reported as the average value of contact angles of at least six data points.